Day One Biopharma's OJEMDA FDA approval for pediatric glioma, but market concerns remain. Check out why I rate DAWN stock as ...

Aeon Biopharma Inc’s profitability metrics reveal strong financial health. The company currently boasts a gross margin of -92.52%. The profit margin, also known as the revenue ratio or gross profit ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

Global healthcare private equity (PE) deal value surged to an estimated $115 billion in 2024, marking the second-highest ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Aardvark Therapeutics plans a $100M IPO for metabolic treatments, targeting rare Prader-Willi syndrome with a potential ...

There is growing enthusiasm about China’s potential to speed up drug development with AI. And companies outside the country ...

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

GV Research Platform (GVRP), a leading provider of preclinical research solutions, has announced a strategic partnership with ...

J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, ...

Q1 2025 Management View CEO Emily Leproust highlighted record revenue of $88.7 million for Q1 2025, representing 24% year-over-year growth and 5% sequential growth. The gross margin expanded to 48.3%, ...